Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic Response Surfaces-Guided Optimization (PRS-OPT) of Propolis-Metformin-Regorafenib Combination Therapy for MASLD-Associated Hepatocellular Carcinoma.

Oncology research - 1 Jan 2026

Huang Yi-Sian, Ma Chung-Yung, Roan Hsiao-Yuh, Chiang Cheng-Hsiung, Tsou Hsiao-Hui, Chen Chen-Hui, Lin Yi-Fan, Wang Horng-Dar, Yuh Chiou-Hwa

Abstract excerpt

Objectives: Hepatocellular carcinoma (HCC) arising in metabolic dysfunction-associated steatotic liver disease (MASLD) develops under lipid-rich stress and inflammatory remodeling, which can alter therapeutic windows. We aimed to determine whether phenotypic response surface-guided optimization (PRS-OPT) can nominate hepatocyte-sparing propolis-metformin-regorafenib (PMR) dose windows that retain antitumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Hep G2 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatocytes

Share to Metformin

Share to Non-alcoholic Fatty Liver Disease

Share to Phenylurea Compounds

Share to Pyridines

Share to Zebrafish

Source

Open in PubMed Open full text

Identifiers

PMID: 42238013
DOI: 10.32604/or.2026.074145
PMCID: PMC13227599

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic Response Surfaces-Guided Optimization (PRS-OPT) of Propolis-Metformin-Regorafenib Combination Therapy for MASLD-Associated Hepatocellular Carcinoma.PMID 42238013Read ↗

A fluorescence-based high-content imaging workflow for multi-parametric lipid droplet phenotyping via Oil Red O fluorescence.Semantic proximity Read ↗

AI-assisted Drug Re-purposing for Human Liver FibrosisSemantic proximity Read ↗

A Systems Biology and Generative Artificial Intelligence Framework for Rational Multi-Target Drug Design in Metabolic Dysfunction-Associated Steatotic Liver Disease: Proof-of-Concept Identification of HPM-001Semantic proximity Read ↗

High-resolution phenotypic profiling of natural products-induced effects on the single-cell level.Semantic proximity Read ↗

Chemical screening of food-related chemicals for human fatty liver risk: Combining high content imaging of cellular responses with in vitro to in vivo extrapolationSemantic proximity Read ↗

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.Semantic proximity Read ↗

Single-cell metabolic profiling reveals subgroups of primary human hepatocytes showing heterogeneous responses to drug challengeSemantic proximity Read ↗

Selective Modulation of Aryl Hydrocarbon Receptor by Coptisine in MAFLDSemantic proximity Read ↗

Cancer cell membrane-coated PLGA nanoparticles deliver lupiwighteone to target EGFR and suppress hepatocellular carcinomaSemantic proximity Read ↗

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell deathSemantic proximity Read ↗

Predicting direct hepatocyte toxicity in humans by combining high-throughput imaging of HepaRG cells and machine learning-based phenotypic profiling.Semantic proximity Read ↗

PKLR-modulating compounds show promising effects for the treatment of hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.